脂质代谢异常和炎症是动脉粥样硬化(athero-sclerosis,AS)发生的主要原因,他汀类药物已被众多大规模临床试验证实是抗AS治疗的基石。过去研究认为,他汀类药物主要是通过抑制肝脏合成胆固醇过程中的关键限速酶——羟甲基戊二酸单酰辅酶A(HMG-CoA)、降低LDL-C水平而达到抗 Lipid metabolism abnormalities and inflammation are the main causes of atherosclerosis (AS). Statins have been confirmed by many large-scale clinical trials as the cornerstone of anti-AS therapy. In the past studies suggest that statins mainly through the inhibition of hepatic synthesis of cholesterol in the process of key rate-limiting enzyme - hydroxymethyl glutaryl coenzyme A (HMG-CoA), lower LDL-C level to achieve resistance